Second and third line phase III trials in mCCR
Phase III trial
N
Dose
Reduction
ORR (%)
Median PFS
(months)
Final Median
OS (months)
Everolimus
vs.
Placebo
723
7 vs 1
1,8 vs. 0
4,9 vs. 1,9
p<0.001
14,8 vs. 14,4
n.s.
Temsirolimus
vs.
Sorafenib
649
16 vs 33
8 vs. 8
4,3 vs. 3,91
n.s.
12,3 vs. 16,6
p=0.01
Axitinib
vs.
Sorafenib
732
31 vs 32
10 vs. 6
4,8 vs. 3.9
p<0.001
15,2 vs. 16,5
n.s.
Cabozantinib
vs.
Everolimus
650
60 vs 25
21 vs. 5
7,4 vs. 3.8
p<0.0000001
21.4 vs. 16.5
p=0.00026
Lenva/Ever
vs
.
Everolimus
153
71 vs 26
43 vs. 6
14,6 vs. 5,5
p<0.001
25,9 vs 15,5
0,065
Nivolumab
vs.
Everolimus
821
8 vs 13
25 vs. 5
4,6 vs. 4,4
n.s.
25 vs. 19,6
0,002
Dovitinib vs. Sorafenib
570
8 vs 10
4 vs. 4
3,7 vs. 3,6
n.s.
11,1 vs 11
n.s.
